LON:N4P N4 Pharma (N4P) Share Price, News & Analysis GBX 0.68 0.00 (0.00%) As of 05/18/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About N4 Pharma Stock (LON:N4P) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get N4 Pharma alerts:Sign Up Key Stats Today's Range 0.60▼ 0.7550-Day Range 0.43▼ 0.6852-Week Range 0.35▼ 1Volume1.32 million shsAverage Volume855,053 shsMarket Capitalization£5.66 millionP/E RatioN/ADividend Yield3.12%Price TargetN/AConsensus RatingN/A Company Overview N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage. N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners. N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform. With an estimated 10 million people globally suffering from Crohn’s disease and ulcerative colitis, the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over $27.6bn by 2030, driven by both increased incidences of the disease and development of new treatments. click here to visit our investor hub https://investors.n4pharma.com/ Read More Receive N4P Stock News and Ratings via Email Sign-up to receive the latest news and ratings for N4 Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. N4P Stock News HeadlinesN4 Pharma advances Nuvec® gene delivery system with key collaborations and patent strengtheningDecember 17, 2025 | msn.comN4 Pharma advances Nuvec® platform with strategic collaborations and patent strengtheningDecember 17, 2025 | msn.comMusk is burning $2.5 billion a quarter on AI. One company holds the key.SpaceX's S-1 filing reveals $7.7 billion spent on AI infrastructure in a single quarter - not chips, not software, but power infrastructure. The filing shows $23.85 billion in servers and $14 billion in construction in progress, all dependent on one company's hardware. Without this supplier, Colossus doesn't run and the $1.25 billion Anthropic pays monthly stops flowing. The stock is still trading like no one has read the filing - but analyst Dylan Jovine has, and he's releasing the name at no cost.June 10 at 1:00 AM | Behind the Markets (Ad)N4 Pharma Advances Targeted RNA Delivery with Nuvec®September 22, 2025 | msn.comN4 Pharma PLC reports change in major holdingsMay 25, 2025 | uk.investing.comN4 Pharma PLCDecember 29, 2024 | barrons.comN4 Pharma’s Nuvec® Platform Shows Promising In Vitro Results for IBD TreatmentDecember 12, 2024 | markets.businessinsider.comN4 Pharma Plc Share Chat (N4P)November 28, 2024 | lse.co.ukSee More Headlines N4P Stock Analysis - Frequently Asked Questions How have N4P shares performed this year? N4 Pharma's stock was trading at GBX 0.50 at the beginning of 2026. Since then, N4P stock has increased by 35.2% and is now trading at GBX 0.68. How were N4 Pharma's earnings last quarter? N4 Pharma Plc (LON:N4P) posted its earnings results on Thursday, September, 25th. The company reported ($0.09) EPS for the quarter. N4 Pharma had a negative trailing twelve-month return on equity of 91.34% and a negative net margin of 15,603.59%. How do I buy shares of N4 Pharma? Shares of N4P stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of N4 Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that N4 Pharma investors own include 4D pharma (DDDD), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP), Coats Group (COA), EQTEC (EQT) and genedrive (GDR). Company Calendar Last Earnings9/25/2025Today6/10/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:N4P CIKN/A Webwww.n4pharma.com Phone+44-1332-690061FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£1.63 million Net Margins-15,603.59% Pretax MarginN/A Return on Equity-91.34% Return on Assets-56.00% Debt Debt-to-Equity RatioN/A Current Ratio23.55 Quick Ratio7.28 Sales & Book Value Annual Sales£7.07 thousand Price / Sales800.95 Cash FlowGBX 0.30 per share Price / Cash Flow2.25 Book ValueGBX 0.45 per share Price / Book1.52Miscellaneous Outstanding Shares832,280,000Free FloatN/AMarket Cap£5.66 million OptionableNot Optionable Beta-0.37 Missed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (LON:N4P) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredForbes calls this a "golden era" for retirement incomeForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLive demo of Elon Musk’s AI agentJeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...Brownstone Research | SponsoredNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding N4 Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share N4 Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
